HK56696A - Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems - Google Patents

Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems

Info

Publication number
HK56696A
HK56696A HK56696A HK56696A HK56696A HK 56696 A HK56696 A HK 56696A HK 56696 A HK56696 A HK 56696A HK 56696 A HK56696 A HK 56696A HK 56696 A HK56696 A HK 56696A
Authority
HK
Hong Kong
Prior art keywords
vesicles
cell
detergent
membrane
vesicle
Prior art date
Application number
HK56696A
Other languages
English (en)
French (fr)
Inventor
Dr Glueck Reinhard
Dr Herrmann Peter
Klein Peter
Original Assignee
Nika Health Products Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Limited filed Critical Nika Health Products Limited
Publication of HK56696A publication Critical patent/HK56696A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feedback Control In General (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Claims (15)

  1. Verfahren für die Herstellung von Fusionspeptide - und gegebenenfalls andere zellspezifische Indikatoren - an der Membran enthaltenden zweischichtigen Phospholipidvesikeln, die ferner wenigstens ein gewünschtes Arzneimittel bzw. eine pharmazeutisch aktive Substanz enthalten, welches folgende Schritte aufweist
    a) Auflösen von Phospholipiden, vorzugsweise zusammen mit den Fusionspeptiden, in Gegenwart eines Detergens,
    b) Zugeben des gewünschten Arzneimittels bzw. Substanz,
    c) Entfernen des Detergens, wodurch die Bildung von Vesikeln verursacht wird,
    d) Behandeln der Vesikeln zur Erzielung einer gewünschten Größe,
    e) Zugeben der Fusionspeptide, außer sie wurden schon unter a) vorgesehen, und
    f) gegebenenfalls Zugeben anderer zellspezifischer Indikatoren, vorzugsweise in Kombination mit einem Vernetzer,
    dadurch gekennzeichnet, daß ein nicht-ionisches Detergens, vorzugsweise Octaäthylenglykol-Monododecyläther, benutzt wird, das mit Hämagglutinin nicht reagiert, das Detergens durch wiederholte Behandlung mit mit Polystyrol geperlten Mikroträgern entfernt wird, und die gewünschte Größe der Vesikeln durch Behandeln mit Ultraschall erzielt wird.
  2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die die Mikroträger eine Mesh-Größe - im feuchten Zustande - von 20 bis 50 haben und die gewünschte Vesikelgröße im Durchmesser 50 bis 100 nm beträgt.
  3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß die Detergenslösung in einer Konzentration zwischen 10 und 250, vorzugsweise zwischen 80 und 120 »mol/ml, verwendet wird und das Detergens durch Anwendung von 1 bis 2, vorzugsweise von etwa 1,5 g, von mit Polystyrol geperlten Mikroträgern pro 100 mg Detergens entfernt wird.
  4. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß die Fusionspeptide aus der aus Hämagglutinin-Trimer oder -Monomer, einem oder beiden seiner gespaltenen Untereinheiten, Glykopeptiden HA1 und HA2, einem aus natürlichen Quellen isolierten Fusionspeptid und einem synthetischen Fusionspeptid bestehenden Gruppe ausgewählt sind.
  5. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß die Vesikeln wenigstens einen - vorzugsweise monoklonalen - Antikörper als zellspezifischen Indikator aufweisen, und vorzugsweise einen Vernetzer, an den der Antikörper derart gebunden ist, daß er biologisch noch voll aktiv ist.
  6. Verfahren nach einem der vorhergehenden Ansprüche, mit Hämagglutinin als Fusionspeptid, dadurch gekennzeichnet, daß das Hämagglutinin von wenigstens einem Vertreter der aus dem Grippevirus, vorzugsweise von der Unterart A-H₁N₁, dem Rhabdovirus, dem Paragrippevirus und dem Togavirus bestehenden Gruppe abgeleitet ist.
  7. Verfahren nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß die Fusionspeptide wenigstens ein Fusionspeptid in der Form einer Sequenz von Aminosäuren aufweist, wobei wenigstens ein Ende der Sequenz von mindestens einer Cysteingruppe gebildet wird, vorzugsweise von drei Cysteingruppen.
  8. Verfahren nach einem der vorhergehenden Ansprüche, bei dem ein Teil der Phospholipide von wenigstens einem Vertreter der aus dem Grippevirus, vorzugsweise von der Unterart A-H₁N₁, dem Rhabdovirus, dem Paragrippevirus und dem Togavirus bestehenden Gruppe abgeleitet ist und in Kombination mit einer 2- bis 100-, vorzugsweise 5- bis 15-fachen, Menge an Phosphatidylcholin angewandt wird.
  9. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß
    - die Phospholipide 70 bis 95 Gewichts-% Phosphatidylcholin und 5 bis 30, vorzugsweise 10 bis 20 Gewichts-%, Phosphatidyl-Äthanolamin aufweisen;
    - 5 bis 10, vorzugsweise 6 bis 8 Gewichts-%, eines Vernetzers, vorzugsweise eines Sulfosuccinimidyl-Derivates,
    - mindestens ein Fusionspeptid, und
    - wenigstens einen zellspezifischen, an den Vernetzer gebundenen Antikörper.
  10. Verfahren nach einem der vorhergehenden Ansprüche, bei dem die Vesikeln wenigstens eine der folgenden Substanzen enthalten: Dextransulfat, Ribonuclease-Dimer, Lysozym-Dimer, Imidazol-Carboxamid, Hydroxy-Harnstoff, Adriplastin, Endoxan, Fluor-Uracil, Colchizin.
HK56696A 1991-02-02 1996-03-28 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems HK56696A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91101414A EP0497997B1 (de) 1991-02-02 1991-02-02 Funktionell aktive Fusionspeptide enthaltende synthetische Membranvesikeln als Arzneistoffabgabesysteme

Publications (1)

Publication Number Publication Date
HK56696A true HK56696A (en) 1996-04-12

Family

ID=8206362

Family Applications (1)

Application Number Title Priority Date Filing Date
HK56696A HK56696A (en) 1991-02-02 1996-03-28 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems

Country Status (22)

Country Link
US (1) US6040167A (de)
EP (1) EP0497997B1 (de)
JP (1) JP3404037B2 (de)
KR (1) KR100205693B1 (de)
AT (1) ATE125154T1 (de)
AU (1) AU657730B2 (de)
BG (1) BG61215B1 (de)
BR (1) BR9204116A (de)
CA (1) CA2079685C (de)
DE (1) DE69111414T2 (de)
DK (1) DK0497997T3 (de)
ES (1) ES2077086T3 (de)
FI (1) FI109969B (de)
GE (1) GEP20002229B (de)
GR (1) GR3017490T3 (de)
HK (1) HK56696A (de)
HU (1) HU215533B (de)
NO (1) NO306194B1 (de)
PL (2) PL296382A1 (de)
RO (1) RO114736B1 (de)
RU (1) RU2125868C1 (de)
WO (1) WO1992013525A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603872A (en) * 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
DK0525132T3 (da) * 1991-02-14 1996-02-05 Baxter Int Binding af genkendende stoffer til liposomer
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
WO1995032706A1 (en) * 1994-05-31 1995-12-07 Inex Pharmaceuticals Corp. Virosome-mediated intracellular delivery of therapeutic agents
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
CZ299809B6 (cs) * 1996-05-08 2008-12-03 Nika Health Products Limited Lipidový vácek mající kladne nabitou membránu z lipidové dvojvrstvy pro prenos genetického materiálu a zpusob jeho prípravy
EP1141007B1 (de) * 1998-12-14 2013-05-15 Dendreon Corporation Zusammensetzungen und methoden zur steigerung der haupthistokompatibilitätskomplex klasse i abhängigen antigen-präsentierung
US7148324B1 (en) 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
JP2004513059A (ja) 1998-12-24 2004-04-30 ユセベ，ソシエテ　アノニム ペプチド産物、方法及び組成物
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CZ20021216A3 (cs) * 1999-10-08 2002-10-16 Nika Health Products Limited Lipidové váčky obsahující DOSPER
JP4112860B2 (ja) * 1999-12-17 2008-07-02 ショット アクチエンゲゼルシャフト 乗員の拘束システムの誘導作動式点火カプセルおよび点火カプセル用のテスト回路
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
AU2003233981A1 (en) * 2002-04-29 2003-11-17 Biotesys Gmbh Transport system in biological systems
EP1447080A1 (de) * 2003-02-13 2004-08-18 Bestewil Holding B.V. Methode zur Herstellung von Virosomen-artigen Partikeln
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
EP4647126A3 (de) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilisierung von pharmazeutischen camptothecinzusammensetzungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
IL86650A0 (en) * 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
AU6358890A (en) * 1989-09-01 1991-04-08 Board Of Regents, The University Of Texas System Immunoliposomes for transmittal of activating signals to cells
AU652778B2 (en) * 1990-10-15 1994-09-08 Quest International B.V. Treatment composition

Also Published As

Publication number Publication date
GEP20002229B (en) 2000-09-25
JPH05505406A (ja) 1993-08-12
RO114736B1 (ro) 1999-07-30
AU657730B2 (en) 1995-03-23
KR100205693B1 (en) 1999-07-01
JP3404037B2 (ja) 2003-05-06
NO306194B1 (no) 1999-10-04
AU1169392A (en) 1992-09-07
FI109969B (fi) 2002-11-15
BG96928A (bg) 1994-03-24
EP0497997B1 (de) 1995-07-19
GR3017490T3 (en) 1995-12-31
HU215533B (hu) 1999-01-28
CA2079685C (en) 2001-11-27
FI924418A7 (fi) 1993-04-03
RU2125868C1 (ru) 1999-02-10
FI924418A0 (fi) 1992-10-01
DE69111414D1 (de) 1995-08-24
PL170169B1 (en) 1996-10-31
NO923703L (no) 1992-11-26
ATE125154T1 (de) 1995-08-15
NO923703D0 (no) 1992-09-24
PL296382A1 (en) 1993-11-02
US6040167A (en) 2000-03-21
HU9203141D0 (en) 1992-12-28
HUT66194A (en) 1994-10-28
BG61215B1 (en) 1997-03-31
BR9204116A (pt) 1993-06-08
ES2077086T3 (es) 1995-11-16
DE69111414T2 (de) 1996-02-01
CA2079685A1 (en) 1992-08-03
WO1992013525A1 (en) 1992-08-20
EP0497997A1 (de) 1992-08-12
DK0497997T3 (da) 1995-11-27

Similar Documents

Publication Publication Date Title
EP0497997B1 (de) Funktionell aktive Fusionspeptide enthaltende synthetische Membranvesikeln als Arzneistoffabgabesysteme
H. Ucisik et al. Emulsomes meet S-layer proteins: an emerging targeted drug delivery system
Karunakaran et al. Emerging trends in lipid-based vaccine delivery: a special focus on developmental strategies, fabrication methods, and applications
US7205273B2 (en) Fusogenic liposomes
CA2212382C (en) Cochleate delivery vehicles
Huckriede et al. Influenza virosomes in vaccine development
AU4221489A (en) Affinity associated vaccine
US4148876A (en) Biological preparations
Kalra et al. Virosomes: as a drug delivery carrier
JP2001523216A (ja) 新規のアジュバント組成物と、それからなるワクチン製剤
Krasnopolsky et al. Licensed liposomal vaccines and adjuvants in the antigen delivery system
de Jonge et al. Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes
CA1079634A (en) Antigens bound to exterior surface of microvesicles
US5897873A (en) Affinity associated vaccine
Rathore et al. Virosomes: a novel vaccination technology
DE69127975T2 (de) Impfstoffe
HU219353B (en) Synthetic membrane vesicles as vehicles containing functionally active fusional peptides and pharmaceutical compositions comprising them
WO1990001947A1 (en) Affinity associated vaccine
Singh et al. 24 Virosomes
CA1334165C (en) Affinity associated vaccine
Fand et al. VIROSOMES AS AN INNOVATIVE DRUG DELIVERY SYSTEM

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)